Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Richard Conway RichardPAConway
3 years 1 month ago
Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW
Richard Conway RichardPAConway
3 years 1 month ago
Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr
Eric Dein ericdeinmd
3 years 1 month ago
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2
Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure.
AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%)
@RheumNow https://t.co/G31PrfqtVu
Eric Dein ericdeinmd
3 years 1 month ago
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS
P3b: SEC 150 mg v SEC 300 v SDZ-ADL
Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance
Hard to assess as overall, low rate of progression
@RheumNow
Richard Conway RichardPAConway
3 years 1 month ago
Lindegren et al. Dairy intake and RA risk in Sweden. Nested case-control. High regular milk intake assoc increased risk (OR 1.90) High cheese assoc decresaed risk (OR 0.52) @RheumNow #ACR22 Abstr#1758 https://t.co/jUz3SJBf4Y https://t.co/ZykW3NjSrK
Janet Pope Janetbirdope
3 years 1 month ago
A spicy result. say NO to turmeric in #rheumatoidarthritis Eat it on food, but don’t expect it to help your joints. @RheumNow #ACR22 https://t.co/1mZBm3rYAA
Richard Conway RichardPAConway
3 years 1 month ago
Utamawatin et al. DB-RCT of Triamcinolone 10mg vs 40mg for knee OA. No difference! Wonder if 10mg would be better than saline? @RheumNow #ACR22 Abstr#1890 https://t.co/vcKze7mSf4 https://t.co/ErEkmUN0Wp
Janet Pope Janetbirdope
3 years 1 month ago
Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in variants that are more prominent ex Omicron strains. But should we use in high risk Pts ex long rituximab users? I do in this group. @RheumNow #ACR22 https://t.co/A8soYbg9ZD
Richard Conway RichardPAConway
3 years 1 month ago
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz
Catherine Sims, MD DrCassySims
3 years 1 month ago
Does tofacitinib work better in patients with PsA and AS who smoke?
Abstract #1036 #ACR22 @RheumNow
🚬519 ever smokers
🚭767 never smokers
💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO
✋Overall, efficacy was generally comparable in ever v. never 🚬
Richard Conway RichardPAConway
3 years 1 month ago
Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months - randomised to continue or stop. Flare 38% vs 17% over 12 months. DAS remission 96% vs 90%. Absence radiograph prog 84% vs 69% @RheumNow #ACR22 Abstr#2013 https://t.co/uOwd8Io5wZ https://t.co/SKWPE7GBrx
Patricia Harkins DrTrishHarkins
3 years 1 month ago
⚡️PNEUMOVAS⚡️
💉reinforced anti pneumococcal vaccine in AAV pts on Rituximab💉
👉Reinforced regimen (double dose PCV13 D0/D7 wt PPV23 @ M5) - sig ⬆️ Ab response 2 strep pneum
❓application 2
👉other vaccines
👉 other RTX tx IMRD
#ACR22 AbstL16 @RheumNow @TerrierBen https://t.co/BnZWAoHDj6
Richard Conway RichardPAConway
3 years 1 month ago
Maksymowych et al. RCT ofAdalimumab for knee OA!? it doesn't work. @RheumNow #ACR22 Abstr#1891 https://t.co/pfPVJ9A1Ex https://t.co/X7sLEaqGvT
Eric Dein ericdeinmd
3 years 1 month ago
@RheumNow video live from #ACR22
Ab0675: Diffuse alveolar hemorrhage in APLS
https://t.co/8BDyxzAGJ2
Janet Pope Janetbirdope
3 years 1 month ago
What’s new w #classification for #APS? You don’t have to have 2 positive tests disseminated in time. BUT remember the the labs for anticardiolipin are shockingly variable btwn centres. @RheumNow #ACR22 https://t.co/NTqQ6h7fws
Poster Hall